Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHANP
- Development stage
- Preclinical
- Lead developer
- CHA Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracerebral
01
Overview
CHANP is a neural progenitor cell (NPC) therapy being developed by CHABiotech for the treatment of Parkinson's disease. This cell therapy candidate utilizes a regenerative medicine approach designed to address the loss of dopaminergic neurons in the substantia nigra. The mechanism involves the transplantation of NPCs, which are intended to differentiate into functional neurons or provide neurotrophic support to existing neural tissue, thereby restoring motor function and promoting neural repair. As of early 2026, the candidate is in the preclinical stages of development.
- Other names
- neural progenitor cellsCHABiotech neural progenitor cell therapy
Beyond the preview
Go deeper on CHANP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHANP.